New pill could offer hope for advanced breast cancer patients

NCT ID NCT06954961

Recruiting now Disease control Sponsor: InventisBio Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial compares a new oral drug, D-0502, against the standard injection fulvestrant for people with ER-positive, HER2-negative advanced or metastatic breast cancer. The study aims to see if D-0502 can delay cancer growth better than fulvestrant. About 640 participants who have already tried hormone therapy will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: D-0502 (oral tablet) and fulvestrant (injection)
What this could lead to: If D-0502 works better than fulvestrant, it could offer a more convenient oral treatment option for people with advanced ER+/HER2- breast cancer, potentially delaying disease progression.
What could go wrong: This is a phase 3 trial, but D-0502 is still experimental. It may not prove superior to fulvestrant, and side effects are not yet fully known. Results may not apply to all breast cancer subtypes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Science
RECRUITING

Beijing, Beijing Municipality, 100021, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150081, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.